Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
Are there any ongoing clinical trials related to endothelial dysfunction and accelerated or premature CAD that patients might be able to enroll in nationwide?
Related Questions
Under what clinical circumstances, if any, would you prescribe fenofibrate along with statin therapy?
What ECG features for ST depression would prompt you to report these ST changes if a patient exercised well and did not have any questions during their stress test?
Should CCTA be considered the diagnostic test of choice in the outpatient evaluation of chest pain?
What patient factors do you consider when selecting between a small interfering RNA, like inclisiran, and PCSK9 inhibitors in patients with recent acute coronary syndrome?
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long-term CVD risk?
What is your approach to a newly diagnosed LBBB in individuals >70 years old who are free of any signs or symptoms of heart disease and without other significant ASCVD risk factors besides age?
When do you think physicians should seriously consider prescribing PCSK9 inhibitors for the prevention of heart attack and stroke in people with ASCVD or diabetes, based on the results of the VESALIUS-CV trial?
How soon after initiating oral anticoagulation therapy for atrial fibrillation can it be interrupted for surgery or procedures?
What should the LDL target be in patients with prediabetes and high lipoprotein (a) with family history of coronary artery disease?
What would be your next diagnostic test of choice for a patient with findings concerning for silent ischemia on noninvasive functional testing in the absence of chest pain?
